Gene info: ID 64839

Gene: FBXL17

GENE ID: 64839

Synonyms: FBXO13|Fbl17|Fbx13

Description: F-box and leucine rich repeat protein 17

Gene type: protein-coding

Location: 5q21.3

dbXrefs: Ensembl:ENSG00000145743 MIM:609083 UniprotKB:Q9UF56

RefSeq: NC_000005.10

Retrived from: SNP Mapped

SNPs: 6 ANCO-SNPs

Phenotype: ND|AD

# Publications: 0

Sherlock p-value : NA (AD) NA (ND) (Frontal_Cortex)

Pascal p-value : 5.723e-1 (AD) 4.369e-1 (ND)

ANCO-SNPs

SNP ID	Position	Alleles	Trait	Variation Type
rs989001	chr5:108340620 (GRCh38.p7)	G>A	nicotine dependence	SNV(Single Nucleotide Variation)
rs12514413	chr5:107988165 (GRCh38.p7)	T>C	nicotine dependence	SNV(Single Nucleotide Variation)
rs10793832	chr5:107984529 (GRCh38.p7)	T>A / T>C	nicotine dependence	SNV(Single Nucleotide Variation)
rs11744308	chr5:107974502 (GRCh38.p7)	A>T	nicotine dependence	SNV(Single Nucleotide Variation)
rs885624	chr5:107964954 (GRCh38.p7)	T>A / T>C	nicotine dependence	SNV(Single Nucleotide Variation)
rs10069340	chr5:107898090 (GRCh38.p7)	G>A	alcohol dependence	SNV(Single Nucleotide Variation)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
PNMA2	0.939
ZNF25	0.932
CAMTA1	0.93
PIGX	0.928
CADM2	0.928
ANKRD46	0.928
UBE2K	0.927
NDFIP1	0.927
AGGF1	0.926
LAMTOR3	0.926

Top 10 negatively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
OR4F5	-0.579
OR4F29	-0.536
CSAG1	-0.479
PPBP	-0.389
RAI14	-0.389
CNN2	-0.387
MAGEA12	-0.382
BEST3	-0.378
S100A12	-0.369
SYDE1	-0.369

There is no DrugBank record for this gene !

ID	Drug Name	Action	PubMed
C111118	2',3,3',4',5-pentachloro-4-hydroxybiphenyl	"2',3,3',4',5-pentachloro-4-hydroxybiphenyl results in decreased expression of FBXL17 mRNA"	19114083
C016403	2,4-dinitrotoluene	"2,4-dinitrotoluene affects the expression of FBXL17 mRNA"	21346803
C023514	2,6-dinitrotoluene	"2,6-dinitrotoluene affects the expression of FBXL17 mRNA"	21346803
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBXL17 mRNA"	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	"[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBXL17 mRNA"	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FBXL17 mRNA"	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBXL17 mRNA"	27188386
C027576	4-hydroxy-2-nonenal	4-hydroxy-2-nonenal results in increased expression of FBXL17 mRNA	19191707
C516138	(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine	"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBXL17 mRNA"	27188386
C516138	(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine	"[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBXL17 mRNA"	27188386
C516138	(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine	"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FBXL17 mRNA"	27188386
C516138	(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine	"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBXL17 mRNA"	27188386
D000082	Acetaminophen	Acetaminophen results in decreased expression of FBXL17 mRNA	21420995\|2223033
D016604	Aflatoxin B1	Aflatoxin B1 affects the expression of FBXL17 protein	20106945
D016604	Aflatoxin B1	Aflatoxin B1 results in decreased expression of FBXL17 mRNA	22100608
D016604	Aflatoxin B1	Aflatoxin B1 results in decreased expression of FBXL17 mRNA	19770486
D018501	Antirheumatic Agents	Antirheumatic Agents results in increased expression of FBXL17 mRNA	24449571
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in decreased expression of FBXL17 mRNA	20064835
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in decreased expression of FBXL17 mRNA	19770486\|2171566
C006780	bisphenol A	bisphenol A results in decreased expression of FBXL17 mRNA	25181051
C006780	bisphenol A	bisphenol A results in increased methylation of FBXL17 gene	28505145
C018475	butyraldehyde	butyraldehyde results in decreased expression of FBXL17 mRNA	26079696
D002220	Carbamazepine	Carbamazepine affects the expression of FBXL17 mRNA	25979313
D020245	p-Chloromercuribenzoic Acid	"[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBXL17 mRNA"	27188386
D020245	p-Chloromercuribenzoic Acid	p-Chloromercuribenzoic Acid results in decreased expression of FBXL17 mRNA	26272509
D002945	Cisplatin	[Cisplatin co-treated with jinfukang] results in decreased expression of FBXL17 mRNA	27392435
D002945	Cisplatin	Cisplatin results in decreased expression of FBXL17 mRNA	27392435
C118739	entinostat	entinostat results in decreased expression of FBXL17 mRNA	26272509
C118739	entinostat	"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBXL17 mRNA"	27188386
D005557	Formaldehyde	Formaldehyde results in decreased expression of FBXL17 mRNA	23649840
D006861	Hydrogen Peroxide	Hydrogen Peroxide results in increased expression of FBXL17 mRNA	18951874
C544151	jinfukang	[Cisplatin co-treated with jinfukang] results in decreased expression of FBXL17 mRNA	27392435
D008741	Methyl Methanesulfonate	Methyl Methanesulfonate results in decreased expression of FBXL17 mRNA	26011545
C046012	pentanal	pentanal results in decreased expression of FBXL17 mRNA	26079696
D010662	Phenylmercuric Acetate	"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FBXL17 mRNA"	27188386
D010662	Phenylmercuric Acetate	Phenylmercuric Acetate results in increased expression of FBXL17 mRNA	26272509
C006253	pirinixic acid	pirinixic acid results in increased expression of FBXL17 mRNA	18301758\|2381119
C017947	sodium arsenite	sodium arsenite affects the expression of FBXL17 mRNA	29319823
D014635	Valproic Acid	"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBXL17 mRNA"	27188386
D014635	Valproic Acid	Valproic Acid affects the expression of FBXL17 mRNA	25979313
D014635	Valproic Acid	Valproic Acid results in decreased expression of FBXL17 mRNA	24383497\|2627250
D014635	Valproic Acid	Valproic Acid results in decreased methylation of FBXL17 gene	29154799
C025643	vinclozolin	vinclozolin results in increased expression of FBXL17 mRNA	23034163

GO/Pathway

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0061630	ubiquitin protein ligase activity	CONTRIBUTES_TO	IBA	21873635

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0031146	SCF-dependent proteasomal ubiquitin-dependent protein catabolic process	-	IBA	21873635

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0005634	nucleus	-	IBA	21873635
GO:0005829	cytosol	-	IBA	21873635
GO:0019005	SCF ubiquitin ligase complex	-	IBA	21873635

KEGG ID	KEGG Term

Reactome ID	Reactome Term	Evidence

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID	Title (Year)	Author	Journal